Identification of Clinical and Laboratory Variables Associated with Cardiotoxicity Events Due to Doxorubicin in Breast Cancer Patients: A 1-Year Follow-Up Study

• Published in: Cardiovascular toxicology Vol. 21; no. 2; pp. 106 - 114
• Main Authors: Simões, Ricardo, Silva, Luciana Maria, de Oliveira, Angélica Navarro, Alves, Michelle Teodoro, Pestana, Rodrigo Mendonça Cardoso, de Souza, Isabella Dâmaris Passos, Oliveira, Heloísa Helena Marques, Soares, Cintia Esteves, Sabino, Adriano de Paula, Gomes, Karina Braga
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.02.2021; Springer; Springer Nature B.V
• Subjects: Adverse events; Antimitotic agents; Antineoplastic agents; Biomarkers; Biomedical and Life Sciences; Biomedicine; Brain natriuretic peptide; Breast cancer; Calcium-binding protein; Cancer; Cancer patients; Cancer therapies; Cardiac patients; Cardiology; Cardiotoxicity; Care and treatment; Chemotherapy; Classification; Doxorubicin; Epidermal growth factor; ErbB-2 protein; Evaluation; Glycosylated hemoglobin; Growth factors; Hematocrit; Hemoglobin; Laboratories; Laboratory tests; Monoclonal antibodies; Natriuretic peptides; Oncology, Experimental; Patients; Pharmacology/Toxicology; Plasma levels; Targeted cancer therapy; Trastuzumab; Triglycerides; Troponin; Troponin I; Laboratory tests; Chemotherapy; Breast cancer; Cardiac markers; Cardiotoxicity; Doxorubicin

Cardiovascular adverse events in patients with breast cancer undergoing chemotherapy (CT) are frequent due to the high cardiotoxic potential of treatments, especially doxorubicin (DOXO). This study aimed to evaluate the association of plasma levels of various biomarkers with cardiotoxicity in women...